ANGO INVESTOR ALERT: AngioDynamics, Inc. Shareholders Encouraged to Contact The Wagner Firm Regarding Investigation

LOS ANGELES--(BUSINESS WIRE)--

The Wagner Firm announces that it is investigating potential claims on behalf of investors of AngioDynamics, Inc. ("AngioDynamics" or the "Company") ANGO concerning the Company's and its officers' possible violations of federal securities laws by misleading investors regarding AngioDynamics' business, operations and prospects.

AngioDynamics is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. The investigation relates to the Company's announcement of its financial results for the third quarter fiscal 2015 on April 9, 2015. The Company reported a quarterly loss of $4.3 million and advised investors of a downgrade in its full year outlook by nearly 4%. On this news, the Company's stock declined by as much as 8% on heavy volume.

If you purchased AngioDynamics shares prior to April 9, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Avi Wagner, Esquire, of The Wagner Firm, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at 310-491-7949, by e-mail at info@thewagnerfirm.com, or visit our website at http://thewagnerfirm.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.